Sanofi India Limited (BOM:500674)

Market Cap	76.14B -46.8%
Revenue (ttm)	17.74B -2.4%
Net Income	3.10B -21.8%
EPS	134.52 -21.8%
Shares Out	23.03M
PE Ratio	24.58
Forward PE	18.74
Dividend	123.00 (3.79%)
Ex-Dividend Date	Apr 22, 2026

Volume	4,634
Open	3,250.85
Previous Close	3,248.05
Day's Range	3,249.60 - 3,335.00
52-Week Range	3,057.60 - 6,399.95
Beta	0.17
Analysts	Buy
Price Target	4,579.00 (+38.5%)
Earnings Date	Jul 24, 2026

About Sanofi India

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also expor...

• Industry: Pharmaceutical Preparations
• Founded: 1956
• Employees: 1,097
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500674

Financial Performance

In 2025, Sanofi India's revenue was 18.37 billion, a decrease of -8.73% compared to the previous year's 20.13 billion. Earnings were 3.27 billion, a decrease of -20.99%.

Analyst Summary

According to 3 analysts, the average rating for 500674 stock is "Buy." The 12-month stock price target is ₹4,579, which is an increase of 38.50% from the latest price.

Price Target

₹4,579

(38.50% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 16, 2026

Data Sources Report a data error